1. Home
  2. PMCB vs DRCT Comparison

PMCB vs DRCT Comparison

Compare PMCB & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.94

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Logo Direct Digital Holdings Inc.

DRCT

Direct Digital Holdings Inc.

HOLD

Current Price

$4.10

Market Cap

8.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMCB
DRCT
Founded
1996
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
8.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
PMCB
DRCT
Price
$0.94
$4.10
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$330.00
AVG Volume (30 Days)
386.6K
7.2M
Earning Date
03-16-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$35,369,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$25.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$1.58
52 Week High
$1.90
$80.85

Technical Indicators

Market Signals
Indicator
PMCB
DRCT
Relative Strength Index (RSI) 57.10 90.17
Support Level $0.84 $1.58
Resistance Level $1.00 $2.98
Average True Range (ATR) 0.09 0.44
MACD 0.01 0.29
Stochastic Oscillator 75.90 70.16

Price Performance

Historical Comparison
PMCB
DRCT

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

Share on Social Networks: